Oncología médica

2020

1. A comprehensive diagnosis of a desmoplastic small round cell tumor of unusual location based on fine-needle aspiration cytology: Report of a case arising in the parotid gland and review of the literature

   Diagnostic Cytopathology, Vol. 48, Núm. 9, pp. 827-832

2. ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort

   Revista Espanola de Patologia, Vol. 53, Núm. 3, pp. 140-148

3. Altered levels of desaturation and ω-6 fatty acids in breast cancer patients’ red blood cell membranes

   Metabolites, Vol. 10, Núm. 11, pp. 1-13

4. Changes in lung cancer survival by TNM stage in the Basque country from 2003 to 2014 according to period of diagnosis

   Cancer Epidemiology, Vol. 65

5. Contextualizing pertuzumab approval in the treatment of HER2-positive breast cancer patients

   Cancer Treatment Reviews, Vol. 83

6. Cross-sectional association between non-soy legume consumption, serum uric acid and hyperuricemia: the PREDIMED-Plus study

   European Journal of Nutrition, Vol. 59, Núm. 5, pp. 2195-2206

7. Current and novel therapeutic opportunities for systemic therapy in biliary cancer

   British Journal of Cancer, Vol. 123, Núm. 7, pp. 1047-1059

8. Effectiveness of physical exercise for people with chronic diseases: the EFIKRONIK study protocol for a hybrid, clinical and implementation randomized trial

   BMC Family Practice, Vol. 21, Núm. 1

9. Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis

   Breast Cancer Research and Treatment, Vol. 180, Núm. 3, pp. 597-609

10. FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: The randomised phase III VISNÚ-1 trial

    ESMO Open, Vol. 5, Núm. 6

11. Factors associated with colon cancer early, intermediate and late recurrence after surgery for stage I–III: A 5-year prospective study

    European Journal of Cancer Care, Vol. 29, Núm. 6

12. MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum

    Journal of Clinical Oncology, Vol. 38, Núm. 32, pp. 3753-3762

13. Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group

    Lung Cancer, Vol. 147, pp. 83-90

14. Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital

    Scientific Reports, Vol. 10, Núm. 1

15. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

    The Lancet Oncology, Vol. 21, Núm. 11, pp. 1413-1422

16. Online farmazia-arreta onkologiaren arloan: eredu pilotu berriak garatzen

    Osagaiz: osasun-zientzien aldizkaria, Vol. 4, Núm. 1, pp. 29-38

17. Predicting Chemotherapy Toxicity in Older Patients with Cancer: A Multicenter Prospective Study

    Oncologist, Vol. 25, Núm. 10, pp. e1516-e1524

18. Preliminary Qualitative and Quantitative Evaluation of DESIREE, a Decision Support Platform for the Management of Primary Breast Cancer Patients

    AMIA ... Annual Symposium proceedings. AMIA Symposium, Vol. 2020, pp. 1012-1021

19. Probabilistic cost-utility analysis and expected value of perfect information for the Oncotype multigenic test: a discrete event simulation model

    Gaceta Sanitaria, Vol. 34, Núm. 1, pp. 61-68

20. Serum levels of hsa-miR-16-5p, hsa-miR-29a-3p, hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-223-3p and subsequent risk of chronic lymphocytic leukemia in the EPIC study

    International Journal of Cancer, Vol. 147, Núm. 5, pp. 1315-1324